Prostatic Neoplasm
Conditions
Keywords
Prostate Specific Antigen, Castration Resistant Prostate Cancer, Adenocarcinoma, Androgen Receptor, Metastases
Brief summary
This study will evaluate an experimental drug called EZN-4176 to determine the anticancer effects when it is given to patients with an advanced form of prostate cancer called castration-resistant prostate cancer (CRPC). Goals of this phase I study include finding out the dose of EZN-4176 that can be safely given without serious side effects and to determine the amount of EZN-4176 that should be given in future studies.
Detailed description
This study will be conducted in two phases: * Phase 1a will involve dose escalation to determine the maximum tolerated dose (MTD). The MTD will be determined on the basis of the results from the safety evaluation. * Phase 1b will involve cohort expansion at one or more dose levels to determine the recommended Phase 2 dose. The recommended Phase 2 dose, which may differ from the MTD, will be determined on the basis of results from safety, activity, and pharmacologic and correlative studies.
Interventions
DRUGEZN-4176
EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
Sponsors
Enzon Pharmaceuticals, Inc.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Capable of understanding protocol requirements & risks & providing written informed consent 2. Histologically or cytologically confirmed diagnosis of metastatic prostate adenocarcinoma 3. Ongoing gonadal androgen-deprivation therapy with LHRH analogs or orchiectomy. Patients without orchiectomy must receive effective LHRH analog therapy during the study 4. Testosterone \< 50 ng/dL 5. Progressive disease after androgen deprivation - with all 3 of the following criteria:PSA evidence of progressive prostate cancer; PSA ≥ 5 ng/mL increasing on at least 2 successive occasions, at least 2 weeks apart. If confirmatory PSA \< screening PSA, additional test for increasing PSA is needed 6. Patients receiving anti-androgen agent as part of primary androgen ablation: disease progression after stopping the anti-androgen agent. This disease progression is defined: 2 consecutive increasing PSAs ≥ 2 weeks apart, or documented osseous or soft tissue progression. Flutamide patients: at least one of the PSAs ≥ 4 weeks after stopping flutamide. Bicalutamide or nilutamide patients: at least one PSA ≥ 6 weeks after stopping the anti-androgen agent. 7. Patients who failed standard therapy or who, after physician discussion, wish to delay chemotherapy 8. Age ≥ 18 yrs 9. ECOG Score: 0-1 10. Albumin ≥3.0 g/dL 11. ANC ≥ 1,500/µL 12. Plts ≥ 75,000/µL 13. Hgb ≥ 9.0 g/dL 14. Serum Creat. ≤ 1.5xULN or Calc Creat. clearance ≥ 60 mL/min 15. Tot bili ≤ 1.5xULN 16. AST; ALT: ≤ 2.5xULN
Exclusion criteria
1. Prostate cancer other than adenocarcinoma, eg. neuroendocrine or small cell histology 2. Concurrent serious medical illness that might interfere with protocol compliance 3. Known chronic infectious disease, eg. AIDS or hepatitis 4. Male patient of reproductive capacity unwilling to use methods appropriate to prevent pregnancy. In the UK, double-barrier contraception required. Patients should continue to use contraception for 3 months after stopping EZN-4176 due to potential for prolonged half-life of EZN-4176 in the liver. 5. History of CNS tumor involvement 6. Other hormonal therapy, eg. megestrol acetate (Megace®), finasteride (Proscar®), dutasteride (Avodart®), or any herbal product known to decrease PSA (e.g., saw palmetto, PC-SPES, and PC-HOPE) 7. \> 10 mg/day of prednisone or equivalent systemic corticosteroid within 4 weeks of first dose of EZN-4176 8. Initiation of bisphosphonates within 4 weeks of enrollment. Patients receiving stable doses of bisphosphonates with subsequent tumor progression may continue to receive this medication; however, initiation of bisphosphonates is not allowed during the study. 9. Therapy with supplements or complementary medicines/botanicals within 4 weeks of first dose of study drug, except for any combination of the following: Conventional multivitamin supplements; Selenium; Lycopene; and Soy supplements 10. Prior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or nitrosoureas) before first dose of EZN-4176 11. Radiation or radioactive treatment within 4 weeks before first dose of EZN-4176. Single-fraction palliative radiation is allowed within 2 weeks before first dose of EZN-4176 12. Lack of recovery from any reversible side effects (except alopecia and Grade 1 or 2 neuropathy) to Grade 0 or 1 toxicity related to administration of an investigational therapeutic agent, chemotherapy, immunotherapy, radiotherapy, or other agents previously used to treat the cancer 13. Current participation in another clinical study with an investigational therapeutic agent and/or use of an investigational therapeutic drug (not including investigational use of an approved drug) in the 30 days before first dose of EZN-4176 14. Inability to comply with study protocol 15. Full anticoagulation therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Determine the Maximum Tolerated Dose (MTD) of EZN-4176 administered as a weekly 1-hour IV infusion. | 2012 | Evaluate incidence, severity and duration of adverse events using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\], Version 4.0, during first cycle. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Determine the recommended Phase 2 dose of EZN-4176 | 2013 | Incidence, severity and duration of adverse events using National Cancer Institute \[NCI\] Common Terminology Criteria for Adverse Events \[CTCAE\], Version 4.0, during all cycles; Objective response, as assessed per recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2). |
Countries
United Kingdom, United States
Outcome results
None listed